MRS. SYDNEY ELIZABETH THOMPSON FNP
Prescription History 1750788113
Nurse Practitioner - Primary Care in Portland, OR

NPI Status: Active since December 01, 2014

Contact Information

3303 SW BOND AVE STE 9
PORTLAND, OR
ZIP 97239
Phone: (503) 494-8573

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. SYDNEY ELIZABETH THOMPSON FNP, an active Primary Care specialist practicing in Portland, OR. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 96 documented patient claims. Among these therapy options, the most frequently utilized medication is Amoxicillin-Clavulanate Potass, which accounts for 20 claims alone.


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 163
OR State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply192
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $192.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.64

State Avg Cost Per Claim

$14.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cephalexin

Generic Formulation: CephalexinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 103
OR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply385
Conservative Utilization

This provider writes prescriptions for this formulation 44.4% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.75

State Avg Cost Per Claim

$9.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 122
OR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills30.3
Peer Average Days Supply615
Conservative Utilization

This provider writes prescriptions for this formulation 29.2% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $83.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.93

State Avg Cost Per Claim

$31.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Mupirocin

Generic Formulation: MupirocinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 120
OR State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply456
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.82

State Avg Cost Per Claim

$10.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Therapeutic Applications

Mupirocin is used to treat certain skin infections (such as impetigo). It is an antibiotic. It works by stopping the growth of certain bacteria.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 70
OR State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.3
Peer Average Days Supply211
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $158.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.32

State Avg Cost Per Claim

$22.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Paxlovid (Eua)

Generic Formulation: Nirmatrelvir/RitonavirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 90
OR State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.7
Peer Average Days Supply110
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.57

State Avg Cost Per Claim

$10.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. The product is also approved to be used in Canada to treat COVID-19. It is used by people who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with nirmatrelvir and ritonavir. Nirmatrelvir is a SARS-CoV-2 main protease inhibitor. It works by preventing the growth of the virus that causes COVID-19. Ritonavir increases (boosts) the levels of nirmatrelvir. This helps nirmatrelvir work better. More information about nirmatrelvir and ritonavir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use and from the Health Canada Patient Medication Information sheet. There is limited information about how safe and effective the combination of nirmatrelvir and ritonavir is for treating COVID-19. Study results show that nirmatrelvir and ritonavir may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of nirmatrelvir and ritonavir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. SYDNEY ELIZABETH THOMPSON FNP provides transparency into local medical care patterns within Portland, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Primary Care** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.